IAM Advisory LLC Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

IAM Advisory LLC bought a new position in Moderna, Inc. (NASDAQ:MRNA) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 821 shares of the company’s stock, valued at approximately $250,000.

Other institutional investors have also recently made changes to their positions in the company. Coatue Management LLC grew its stake in Moderna by 388.3% in the second quarter. Coatue Management LLC now owns 6,140,904 shares of the company’s stock valued at $1,442,990,000 after purchasing an additional 4,883,219 shares during the last quarter. Lone Pine Capital LLC acquired a new stake in Moderna in the second quarter worth about $937,781,000. Renaissance Technologies LLC boosted its holdings in Moderna by 94.9% in the second quarter. Renaissance Technologies LLC now owns 3,188,454 shares of the company’s stock worth $749,223,000 after acquiring an additional 1,552,925 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Moderna by 30,664.5% in the second quarter. Macquarie Group Ltd. now owns 1,514,535 shares of the company’s stock worth $355,886,000 after acquiring an additional 1,509,612 shares in the last quarter. Finally, FMR LLC boosted its holdings in Moderna by 25.2% in the second quarter. FMR LLC now owns 7,215,019 shares of the company’s stock worth $1,695,385,000 after acquiring an additional 1,452,440 shares in the last quarter. Hedge funds and other institutional investors own 55.10% of the company’s stock.

MRNA opened at $273.39 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.35 and a quick ratio of 1.25. The firm has a fifty day moving average price of $325.92 and a 200 day moving average price of $302.32. Moderna, Inc. has a 1 year low of $98.65 and a 1 year high of $497.49. The stock has a market cap of $110.85 billion, a P/E ratio of 16.76, a P/E/G ratio of 0.34 and a beta of 1.32.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 4th. The company reported $7.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.49 by ($1.79). Moderna had a net margin of 59.69% and a return on equity of 121.61%. The firm had revenue of $4.97 billion during the quarter, compared to analyst estimates of $6.29 billion. During the same quarter in the prior year, the firm earned ($0.59) earnings per share. The business’s revenue for the quarter was up 3065.0% on a year-over-year basis. Equities analysts expect that Moderna, Inc. will post 26.58 EPS for the current year.

In related news, insider Juan Andres sold 5,000 shares of the business’s stock in a transaction on Friday, August 27th. The shares were sold at an average price of $398.12, for a total value of $1,990,600.00. Following the completion of the sale, the insider now owns 5,000 shares of the company’s stock, valued at approximately $1,990,600. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction on Monday, November 15th. The stock was sold at an average price of $231.01, for a total transaction of $3,465,150.00. The disclosure for this sale can be found here. In the last three months, insiders sold 427,250 shares of company stock valued at $148,469,635. 19.40% of the stock is owned by insiders.

Several equities research analysts have weighed in on MRNA shares. Deutsche Bank Aktiengesellschaft started coverage on Moderna in a report on Friday, October 22nd. They issued a “sell” rating and a $250.00 price target for the company. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a report on Thursday, August 5th. Piper Sandler decreased their target price on Moderna to $348.00 and set an “overweight” rating for the company in a report on Friday, November 5th. Morgan Stanley decreased their target price on Moderna from $337.00 to $313.00 and set an “equal weight” rating for the company in a report on Friday, November 5th. Finally, Wolfe Research initiated coverage on Moderna in a report on Monday, November 8th. They set an “outperform” rating and a $304.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $243.93.

About Moderna

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Further Reading: How to find the components of the quick ratio

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.